GeoVax Labs faces Nasdaq delisting over low stock price

What happened

GeoVax Labs, Inc. (Nasdaq: GOVX), a pharmaceutical company focused on developing vaccines and immunotherapies, disclosed in an August 28, 2026 SEC filing that it received a delisting determination from Nasdaq. The notice, dated August 27, 2026, said the company's common stock failed to meet Nasdaq's minimum bid price requirement for continued listing.

According to the filing, the closing bid price of GeoVax's common stock was below $1.00 per share for 30 consecutive business days, from July 16, 2026 through August 26, 2026. Nasdaq determined this violates Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

The company stated it intends to request a hearing before the Nasdaq Hearings Panel by the September 3, 2026 deadline. A timely request would stay any suspension until the panel makes a decision. Trading is expected to be suspended at the opening of business on September 8, 2026, if no hearing is requested.

On the day of the filing, the stock closed at $0.483, down 4.73% from the previous close of $0.507.

Why it matters

This is not the first listing issue for GeoVax. The filing notes that the company had previously received a notice from Nasdaq about failing to meet the minimum $2,500,000 stockholders' equity requirement under Listing Rule 5550(b).

Additionally, Nasdaq said GeoVax is not eligible for the standard 180-day grace period to regain compliance because the company executed a 1-for-25 reverse stock split on January 12, 2026. Under Nasdaq rules, companies that have done a reverse split within the prior year are not given that usual cure period if they fall below $1.00 again.

The company's plan to request a hearing does not guarantee a favorable outcome. GeoVax itself cautions that there can be no assurance the Hearings Panel will allow continued listing or that the company will regain compliance with all Nasdaq requirements.

What this means

This event is a delisting notice, which is a formal step Nasdaq takes when a company fails to meet its listing standards. An 8-K is a form companies file with the SEC to announce major events, and Item 3.01 is specifically used to disclose a delisting notice or failure to satisfy a listing rule.

The minimum bid price rule is straightforward: a stock must close at or above $1.00 per share for at least 30 consecutive business days. GeoVax fell short of that benchmark.

The reverse stock split is a corporate action that reduces the number of shares outstanding and raises the price per share proportionally. GeoVax did a 1-for-25 split in January, but the stock price later dropped back below $1.00. Nasdaq's rule denies a second 180-day compliance period in such cases, meaning the company faces a stricter timeline.

Normally, a company that receives a delisting determination can appeal by requesting a hearing. That request typically pauses any suspension until the panel rules. GeoVax has said it will do that, so the stock is likely to keep trading during the appeal, but the future listing is uncertain.